HOME Top Market Reports Immunotherapy Drugs Market by Type of Drugs (Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha), Therapy Area (Cancer, Autoimmune Diseases, Infectious Diseases), End-User (Hospitals), Region (North America, Asia-Pacific) - Global Forecast to 2021

Immunotherapy Drugs Market by Type of Drugs (Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha), Therapy Area (Cancer, Autoimmune Diseases, Infectious Diseases), End-User (Hospitals), Region (North America, Asia-Pacific) - Global Forecast to 2021

By: marketsandmarkets.com
Publishing Date: January 2017
Report Code: PH 3926

 

  Speak to Analyst Enquiry Before Buying Webinar
purchase report
download pdf  request for customisation


The global immunotherapy drugs market is projected to reach USD 201.52 Billion by 2021 from USD 108.41 Billion in 2016, growing at a CAGR of 13.5% during the forecast period of 2016 to 2021.

Increasing adoption of targeted therapies with fewer side effects, quicker drug approval processes, and high prevalence rate of lifestyle diseases are major growth drivers of this market. On the other hand, the high cost of immunotherapy treatment, and high attrition rate in the product development cycle are the major factors hindering the growth of the market.  However, rising opportunities in the emerging markets, and immunotherapy as an alternative to chemotherapy for first line treatment are the factors supporting the growth of the market.

In this report, the immunotherapy drugs market is segmented on the basis of type of drugs, therapy area, end user, and region. Based on end user, the market is segmented into hospitals, clinics, and others.

On the basis of therapy area, the immunotherapy drugs market is segmented into cancer, autoimmune & inflammatory diseases, infectious diseases, and others. Among these segments, the cancer segment is expected to account for the largest market share in 2016. Cancer segment is also expected to be the fastest growing segment in the market, by therapy area in 2016. The large share and high growth of this segment can be attributed to factor such as high preference for immunotherapy as a first line of treatment in cancer leading to growing demand for immunotherapy drugs.

North America is expected to account for largest share in the immunotherapy drugs market, by region in 2016. Asia-Pacific is expected to be the fastest-growing regional segment in the market. The high growth of this segment can primarily be attributed to the low cost of manufacturing and acceptable regulatory scenario in this region.

The major players operating in the immunotherapy drugs market include F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline (U.K.), AbbVie, Inc. (U.S.), Amgen, Inc. (U.S.), Merck & Co., Inc. (U.S.). Bristol-Myers Squibb (U.S.), Novartis International AG (Switzerland), Eli Lilly and Company (U.S.), Johnson & Johnson (U.S.), and AstraZeneca plc (U.K.).

Target Audience

  • Pharmaceuticals Manufacturers
  • Research & Academic Institutions
  • Hospitals and clinics
  • Contract Manufacturers
  • Contract Research Organizations

To know about the assumptions considered for the study, download the pdf brochure

Scope of the Report

Particular

Scope

Region

  • North America
  • Europe
  • Asia- Pacific
  • RoW

Base Year

2015

Forecast Period

2016-2021

Revenue Currency

USD

This research report categorizes the immunotherapy drugs market into the following segments and subsegment:

Immunotherapy drugs Market, by Therapy Area

  • Cancer
    • Solid Tumor
    • Malignant
  • Autoimmune & Inflammatory Diseases
  • Infectious Diseases
  • Others

Immunotherapy drugs Market, by Type of Drugs

  • Monoclonal Antibodies
  • Adult Vaccines
    • Preventive Vaccines
    • Therapeutic Vaccines
  • Checkpoint Inhibitors
  • Interferons Alpha & Beta
  • Interleukins
  • Others

Immunotherapy drugs Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
  • Asia-Pacific

Rest of the World (RoW)

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Geographic Analysis

  • Further breakdown of the Immunotherapy Drugs market into specific countries/regions in Asia, Europe, and Rest of The World

Company Information

  • Detailed analysis and profiling of additional market players (Up to 5)

Table of Contents

1 Introduction (Page No. - 15)
    1.1 Objectives of the Study
    1.2 Market Definition
           1.2.1 Markets Covered
           1.2.2 Years Considered for the Study
    1.3 Currency '
    1.4 Limitations
    1.5 Stakeholders

2 Research Methodology (Page No. - 18)
    2.1 Market Size Estimation
    2.2 Market Breakdown and Data Triangulation
    2.3 Market Share Estimation
           2.3.1 Key Data From Secondary Sources
           2.3.2 Key Data From Primary Sources
           2.3.3 Assumptions for the Study

3 Executive Summary (Page No. - 25)
    3.1 Introduction
    3.2 Conclusion

4 Premium Insights (Page No. - 30)
    4.1 Global Immunotherapy Drugs Market Overview
    4.2 Market: By Therapy Area & Region
    4.3 Market: Geographic Snapshot
    4.4 Market, By Type of Drug
    4.5 Life Cycle Analysis, By Region (2016)

5 Market Overview (Page No. - 33)
    5.1 Introduction
           5.1.1 Drivers
                    5.1.1.1 Increasing Adoption of Targeted Therapy Over Traditional Therapy
                    5.1.1.2 Emergence of Biosimilars
                    5.1.1.3 Increasing Demand for Mabs
                    5.1.1.4 High Prevalence Rate of Lifestyle Diseases
                    5.1.1.5 Fast Track and Orphan Drug Designations
           5.1.2 Restraints
                    5.1.2.1 High Cost of Immunotherapy Treatment
                    5.1.2.2 High Attrition Rate in the Product Development Cycle
           5.1.3 Opportunities
                    5.1.3.1 Emerging Markets
                    5.1.3.2 Immunotherapy to Replace Chemotherapy in Cancer Treatment
           5.1.4 Challenge
                    5.1.4.1 Impending Patent Expiry of Top-Selling Biologics

6 Industry Insights (Page No. - 39)
    6.1 Introduction
    6.2 Epidemiology Coverage
           6.2.1 Cancer Epidemiology
           6.2.2 Autoimmune Disease Epidemiology
    6.3 Pricing and Reimbursement Scenario
           6.3.1 U.S.
           6.3.2 U.K.
           6.3.3 France
           6.3.4 Germany
           6.3.5 Other European Countries
           6.3.6 Japan
    6.4 Research Funding & Government Initiatives
    6.5 Pipeline Drugs
           6.5.1 Phase 1
           6.5.2 Phase I/II
           6.5.3 Phase II
           6.5.4 Phase II/III
           6.5.5 Phase III
           6.5.6 Application Submitted
           6.5.7 Promising Molecules
    6.6 Industry Trends
    6.7 Key Products Expected to Be Launched
    6.8 Treatment Protocols and Line of Therapies
           6.8.1 First-Line Therapy
           6.8.2 Second-Line Therapy
           6.8.3 Other Treatments
    6.9 Burning Issues

7 Immunotherapy Drugs Market, By Type of Drug (Page No. - 67)
    7.1 Introduction
    7.2 Monoclonal Antibodies
    7.3 Adult Vaccines
           7.3.1 Preventive Vaccines
           7.3.2 Therapeutic Vaccines
    7.4 Checkpoint Inhibitors
    7.5 Interferons Alpha & Beta
    7.6 Interleukins
    7.7 Other Drugs

8 Immunotherapy Drugs Market, By Therapy Area (Page No. - 79)
    8.1 Introduction
    8.2 Cancer
    8.3 Autoimmune and Inflammatory Diseases
    8.4 Infectious Diseases
    8.5 Other Therapy Areas

9 Immunotherapy Drugs Market, By End User (Page No. - 88)
    9.1 Introduction
    9.2 Hospitals
    9.3 Clinics
    9.4 Other End Users

10 Immunotherapy Drugs Market, By Region (Page No. - 93)
     10.1 Introduction
     10.2 North America
             10.2.1 U.S.
             10.2.2 Canada
     10.3 Europe
             10.3.1 Germany
             10.3.2 U.K.
             10.3.3 France
             10.3.4 Italy
             10.3.5 Spain
     10.4 Asia-Pacific
             10.4.1 Japan
             10.4.2 China
             10.4.3 India
     10.5 Rest of the World (RoW)

11 Competitive Landscape (Page No. - 116)
     11.1 Introduction
     11.2 Strategic Analysis
     11.3 Market Share Analysis
     11.4 Competitive Situation and Trends
             11.4.1 Regulatory Approvals
             11.4.2 Collaborations
             11.4.3 Agreements
             11.4.4 Acquisitions
             11.4.5 Expansions

12 Company Profiles (Page No. - 124)
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
     12.1 Introduction
     12.2 F. Hoffmann-La Roche AG
     12.3 Merck & Co., Inc.
     12.4 Novartis International AG
     12.5 Johnson & Johnson (A Parent Company of Janssen Biotech, Inc.)
     12.6 Glaxosmithkline PLC
     12.7 Amgen Inc.
     12.8 Abbvie
     12.9 Astrazeneca
     12.10 Bristol-Myers Squibb
     12.11 ELI Lilly and Company

*Details on Marketsandmarkets View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies.

13 Appendix (Page No. - 157)
     13.1 Insights of Industry Experts
     13.2 Discussion Guide
     13.3 Other Developments
     13.4 Knowledge Store: Marketsandmarkets’ Subscription Portal
     13.5 Introducing RT: Real-Time Market Intelligence
     13.6 Available Customizations
     13.7 Related Reports
     13.8 Author Details


List of Tables (79 Tables)

Table 1 Immunotherapy Drugs Market Summary
Table 2 Comparison of Cost (Branded vs Biosimilar Version)
Table 3 Cancer: Estimated Incidence, Mortality in Men (2015)
Table 4 Cancer: Estimated Incidence, Mortality in Women (2015)
Table 5 Global Market Size, By Type of Drug, 2014–2021 (USD Billion)
Table 6 Global Monoclonal Antibodies Market Size, By Region, 2014–2021 (USD Billion)
Table 7 North America: Monoclonal Antibody Market Size, By Country, 2014–2021 (USD Billion)
Table 8 Global Adult Vaccines Market Size, By Type, 2014–2021 (USD Billion)
Table 9 Global Adult Vaccines Market Size, By Region, 2014–2021 (USD Billion)
Table 10 North America: Adult Vaccines Market Size, By Country, 2014–2021 (USD Billion)
Table 11 Global Preventive Vaccines Market Size, By Region, 2014–2021 (USD Billion)
Table 12 North America: Preventive Vaccines Market Size, By Country, 2014–2021 (USD Billion)
Table 13 Global Therapeutic Vaccines Market Size, By Region, 2014–2021 (USD Billion)
Table 14 North America: Therapeutic Vaccines Market Size, By Country, 2014–2021 (USD Billion)
Table 15 Global Checkpoint Inhibitors Market Size, By Region, 2014–2021 (USD Billion)
Table 16 North America: Checkpoint Inhibitors Market Size, By Country, 2014–2021 (USD Billion)
Table 17 Global Interferons Alpha & Beta Market Size, By Region, 2014–2021 (USD Billion)
Table 18 North America: Interferons Alpha & Beta Market Size, By Country, 2014–2021 (USD Billion)
Table 19 Global Other Drugs Market Size, By Region, 2014–2021 (USD Billion)
Table 20 North America: Other Drugs Market Size, By Country, 2014–2021 (USD Billion)
Table 21 Global Market Size, By Therapy Area, 2014–2021 (USD Billion)
Table 22 Global Market Size for Cancer, By Type, 2014–2021 (USD Billion)
Table 23 GlobalMarket Size for Cancer, By Region, 2014–2021 (USD Billion)
Table 24 North America: Global Market Size for Cancer, By Country, 2014–2021 (USD Billion)
Table 25 Global Cancer Market Size for Solid Tumors, By Region, 2014–2021 (USD Billion)
Table 26 North America: Global Cancer Market Size for Solid Tumors, By Country, 2014–2021 (USD Billion)
Table 27 Global Cancer Market Size for Malignant Tumors, By Region, 2014–2021 (USD Billion)
Table 28 North America: Global Cancer Market Size for Malignant Tumors, By Country, 2014–2021 (USD Billion)
Table 29 Global Market Size for Autoimmune and Inflammatory Diseases, By Region, 2014–2021 (USD Billion)
Table 30 North America: Global Market Size for Autoimmune and Inflammatory Diseases, By Country, 2014–2021 (USD Billion)
Table 31 Global Market Size for Infectious Diseases, By Region, 2014–2021 (USD Billion)
Table 32 North America: Global Market Size for Infectious Diseases, By Country, 2014–2021 (USD Billion)
Table 33 Global Market Size for Other Therapy Areas, By Region, 2014–2021 (USD Billion)
Table 34 North America: Global Market Size for Other Therapy Areas, By Country, 2014–2021 (USD Billion)
Table 35 Global Market Size, By End User, 2014–2021 (USD Billion)
Table 36 Global Market Size for Hospitals, By Region, 2014–2021 (USD Billion)
Table 37 North America: Global Market Size for Hospitals, By Country, 2014–2021 (USD Billion)
Table 38 Global Immunotherapy Drugs Market Size for Clinics, By Region, 2014–2021 (USD Billion)
Table 39 North America: Global Immunotherapy Drugs Market Size for Clinics, By Country, 2014–2021 (USD Billion)
Table 40 Global Immunotherapy Drugs Market Size for Other End Users, By Region, 2014–2021 (USD Billion)
Table 41 North America: Global Immunotherapy Drugs Market Size for Other End Users, By Country, 2014–2021 (USD Billion)
Table 42 Global Immunotherapy Drugs Market Size, By Region, 2014–2021 (USD Billion)
Table 43 North America: Immunotherapy Drugs Market Size, By Country, 2014–2021 (USD Billion)
Table 44 North America: Immunotherapy Drugs Market Size, By Type of Drug, 2014–2021 (USD Billion)
Table 45 North America: Adult Vaccines Market Size, By Type, 2014–2021 (USD Billion)
Table 46 North America: Immunotherapy Drugs Market Size, By Therapy Area, 2014–2021 (USD Billion)
Table 47 North America: Immunotherapy Drugs Market Size for Cancer, By Type, 2014–2021 (USD Billion)
Table 48 North America: Immunotherapy Drugs Market Size, By End User, 2014–2021 (USD Billion)
Table 49 U.S.: Immunotherapy Drugs Market Size, By Type of Drug, 2014–2021 (USD Billion)
Table 50 U.S.: Adult Vaccines Market Size, By Type, 2014–2021 (USD Billion)
Table 51 The U.S.: Immunotherapy Drugs Market Size, By Therapy Area, 2014–2021 (USD Billion)
Table 52 U.S.: Immunotherapy Drugs Market Size for Cancer, By Type, 2014–2021 (USD Billion)
Table 53 The U.S.: Immunotherapy Drugs Market Size, By End User, 2014–2021 (USD Billion)
Table 54 Canada: Immunotherapy Drugs Market Size, By Type of Drug, 2014–2021 (USD Billion)
Table 55 Canada: Adult Vaccines Market Size, By Type, 2014–2021 (USD Billion)
Table 56 Canada: Immunotherapy Drugs Market Size, By Therapy Area, 2014–2021 (USD Billion)
Table 57 Canada: Immunotherapy Drugs Market Size for Cancer, By Type, 2014–2021 (USD Billion)
Table 58 Canada: Immunotherapy Drugs Market Size, By End User, 2014–2021 (USD Billion)
Table 59 Europe: Immunotherapy Drugs Market Size, By Type of Drug, 2014–2021 (USD Billion)
Table 60 Europe: Adult Vaccines Market Size, By Type, 2014–2021 (USD Billion)
Table 61 Europe: Immunotherapy Drugs Market Size, By Therapy Area, 2014–2021 (USD Billion)
Table 62 Europe: Immunotherapy Drugs Market Size for Cancer, By Type, 2014–2021 (USD Billion)
Table 63 Europe: Immunotherapy Drugs Market Size, By End User, 2014–2021 (USD Billion)
Table 64 APAC.: Immunotherapy Drugs Market Size, By Type of Drug, 2014–2021 (USD Billion)
Table 65 APAC: Adult Vaccines Market Size, By Type, 2014–2021 (USD Billion)
Table 66 APAC: Immunotherapy Drugs Market Size, By Therapy Area, 2014–2021 (USD Billion)
Table 67 APAC: Immunotherapy Drugs Market Size for Cancer, By Type, 2014–2021 (USD Billion)
Table 68 APAC: Immunotherapy Drugs Market Size, By End User, 2014–2021 (USD Billion)
Table 69 RoW: Immunotherapy Drugs Market Size, By Type of Drug, 2014–2021 (USD Billion)
Table 70 RoW: Adult Vaccines Market Size, By Type, 2014–2021 (USD Billion)
Table 71 RoW: Immunotherapy Drugs Market Size, By Therapy Area, 2014–2021 (USD Billion)
Table 72 RoW: Immunotherapy Drugs Market Size for Cancer, By Type, 2014–2021 (USD Billion)
Table 73 RoW: Immunotherapy Drugs Market Size, By End User, 2014–2021 (USD Billion)
Table 74 Market Developments, 2013–2016
Table 75 Approvals, 2013–2016
Table 76 Collaborations, 2013–2016
Table 77 Agreements, 2013–2016
Table 78 Acquisitions, 2013–2016
Table 79 Expansions, 2013–2016


List of Figures (44 Figures)

Figure 1 Research Design
Figure 2 Market Size Estimation Methodology: Bottom-Up Approach
Figure 3 Market Size Estimation Methodology: Top-Down Approach
Figure 4 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 5 Data Triangulation Methodology
Figure 6 Immunotherapy Drugs Market Size, By Type of Drug, 2016 vs 2021 (USD Billion)
Figure 7 Immunotherapy Drugs Market Size, By Therapy Area, 2016 vs 2021 (USD Billion)
Figure 8 Immunotherapy Drugs Market Size, By End User, 2016 vs 2021 (USD Billion)
Figure 9 Immunotherapy Drugs Market, By Region, 2016
Figure 10 Immunotherapy Drugs Market Size, By Region, 2016 vs 2021 (USD Billion)
Figure 11 Increasing Adoption of Target Therapy Over Traditional Therapy to Drive Market Growth
Figure 12 Cancer to Command the Largest Market Share in 2016
Figure 13 Asia to Register Highest Growth During the Forecast Period
Figure 14 Checkpoint Inhibitors Expected to Be the Fastest-Growing Segment
Figure 15 Asia Presents Lucrative Growth Opportunities in the Immunotherapy Drugs Market
Figure 16 Increasing Adoption of Targeted Therapy Over Traditional Therapy Will Drive the Immunotherapy Drugs Market
Figure 17 Rise in Costs of Cancer Immunotherapy Drugs
Figure 18 Percentage of Adult Population Diagnosed With Autoimmune Diseases (October 2016)
Figure 19 Cancer Research Funding in 2014
Figure 20 Clinical Phases of Products to Be Launched
Figure 21 Monoclonal Antibodies Segment to Account for the Largest Market Share in 2016
Figure 22 Preventive Vaccines to Account for the Largest Share in 2016
Figure 23 Global Interleukins Market Size, 2016–2021 (USD Billion)
Figure 24 Cancer Account for the Largest Market Share in 2016
Figure 25 Hospitals to Dominate the Immunotherapy Drugs Market, By End User, During 2016–2021
Figure 26 Geographic Snapshot: Asia-Pacific, the Fastest-Growing Region in 2016–2021
Figure 27 Checkpoint Inhibitors Segment to Witness High Growth in the North American and Asia-Pacific Markets
Figure 28 North America: Immunotherapy Drugs Market Snapshot
Figure 29 U.S. to Dominate the North American Immunotherapy Drugs Market
Figure 30 Europe: Immunotherapy Drugs Market Snapshot
Figure 31 APAC: Immunotherapy Drugs Market Snapshot
Figure 32 Key Developments in the Immunotherapy Drugs Market, 2013–2016
Figure 33 Immunotherapy Drugs Market Share Analysis, By Key Player, 2015
Figure 34 Geographic Revenue Mix of the Top Five Market Players
Figure 35 F. Hoffmann-La Roche AG: Company Snapshot
Figure 36 Merck & Co., Inc.: Company Snapshot
Figure 37 Novartis International AG: Company Snapshot
Figure 38 Johnson & Johnson: Company Snapshot
Figure 39 Glaxosmithkline PLC: Company Snapshot
Figure 40 Amgen Inc.: Company Snapshot
Figure 41 Abbvie: Company Snapshot
Figure 42 Astrazeneca: Company Snapshot
Figure 43 Bristol-Myers Squibb: Company Snapshot
Figure 44 ELI Lilly and Company: Company Snapshot

The global immunotherapy drugs market is projected to reach USD 201.52 Billion by 2021 from USD 108.41 Billion in 2016, growing at a CAGR of 13.5% during the forecast period of 2016 to 2021.

Increasing adoption of targeted therapies with fewer side effects, quicker drug approval processes, and high prevalence rate of lifestyle diseases are major growth drivers of this market. On the other hand, the high cost of immunotherapy treatment, and high attrition rate in the product development cycle are the major factors hindering the growth of the market.  However, rising opportunities in the emerging markets, and immunotherapy as an alternative to chemotherapy for first line treatment are the factors supporting the growth of the market.

The immunotherapy drugs market is segmented on the basis of type of drugs, therapy area, end user, and region. Based on type of drugs, the market is segmented into monoclonal antibodies, adult vaccines, checkpoint inhibitors, interferons alpha & beta, interleukins, and others. Adult vaccines segment is further categorized into preventive vaccines and therapeutic vaccines. Monoclonal antibodies segment is expected to account for the largest market share in the market, by type of drugs in 2016. On the other hand, checkpoint inhibitors segment is expected to be the fastest growing segment in the market, by type of drugs, in 2016. The high growth of this segment can be attributed to factors such as increasing adoption of checkpoint inhibitors in cancer treatment with their ability to target only foreign cells leaving normal cells alone.

On the basis of therapy area, the immunotherapy drugs market is segmented into cancer, autoimmune & inflammatory diseases, infectious diseases, and others. Among these segments, the cancer segment is expected to account for the largest market share in 2016. Cancer segment is also expected to be the fastest growing segment in the market, by therapy area in 2016. The large share and high growth of this segment can be attributed to factor such as high preference for immunotherapy as a first line of treatment in cancer leading to growing demand for immunotherapy drugs.

Immunotherapy Drugs Market

North America is expected to account for largest share in the immunotherapy drugs market, by region in 2016. Asia-Pacific is expected to be the fastest-growing regional segment in the market. The high growth of this segment can primarily be attributed to the low cost of manufacturing and acceptable regulatory scenario in this region.

The major players operating in the immunotherapy drugs market include F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline (U.K.), AbbVie, Inc. (U.S.), Amgen, Inc. (U.S.), Merck & Co., Inc. (U.S.). Bristol-Myers Squibb (U.S.), Novartis International AG (Switzerland), Eli Lilly and Company (U.S.), Johnson & Johnson (U.S.), and AstraZeneca plc (U.K.).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit https://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports



Access reports on all high
growth Pharmaceuticals Markets on KnowledgeStore
Request Demo